NCT00688480

Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 67 (actual)
• Sponsor: A. D. Struthers · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries. Allopurinol, a drug used safely in the treatment of gout for many years, has been found to dramatically reduce "oxidative stress". It is therefore hoped that it also reduce the thickened heart muscle and stiffened arteries. If it did, it is likely to reduce the appallingly high cardiac death rate in this group of kidney disease patients.

Conditions

• Kidney Disease
• Left Ventricular Hypertrophy

Interventions

Type	Name	Description
DRUG	Placebo	1 capsule, orally for 9 months
DRUG	Allopurinol	Allopurinol 300 mg once/day orally, 9 months

Timeline

• Start date: 2008-01-01
• Primary completion: 2009-08-01
• Completion: 2010-02-01
• First posted: 2008-06-03
• Last updated: 2016-11-03

Locations

1 site across 1 country: United Kingdom